Kathryn Romano, Chief Accounting Officer at Krystal Biotech, Inc. (KRYS), sold 10,607 shares at $163.68 ($1.8M) on 2024-02-28, disclosed to the SEC on 2024-03-01.
Scheduled sale ($1.8M) by Chief Accounting Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $162.71 | 648 | $105K | 6.0% |
| 2 | $162.71 | 648 | $105K | 6.0% |
| 3 | $163.08 | 2,314 | $377K | 21.5% |
| 4 | $163.68 | 900 | $147K | 8.4% |
| 5 | $164.81 | 1,429 | $236K | 13.4% |
| 6 | $164.81 | 1,429 |
| $236K |
| 13.4% |
| 7 | $166.06 | 300 | $50K | 2.8% |
| 8 | $167.85 | 300 | $50K | 2.9% |
| 9 | $169.09 | 1,216 | $206K | 11.7% |
| 10 | $169.09 | 1,216 | $206K | 11.7% |
| 11 | $169.82 | 117 | $20K | 1.1% |
| 12 | $172.23 | 90 | $16K | 0.9% |
| Total | $165.30 avg | 10,607 | $1.8M | 100% |
| Filing → |
| KRYS | SELL | 2025-02-28 | $131K | — | Filing → |
| KRYS | SELL | 2024-03-01 | $1.8M | — | Filing → |
| KRYS | SELL | 2024-02-28 | $1.1M | — | Filing → |